Abstract
Background: Diarrhea-associated hemolytic uremic syndrome (D+HUS) causes acute renal failure. Neutrophil gelatinase-associated lipocalcin (NGAL) is an early indicator of kidney injury. Objective: To determine if urinary NGAL excretion is a biomarker of severe renal injury and predicts the need for dialysis in D+HUS. Methods: Patients were randomly selected from among participants in the SYNSORB Pk trial. Urine samples were collected daily if available during the first week of hospitalization. NGAL levels were determined by ELISA. Results: 34 children, age 5.9±3.9 yr, were studied; ten (29%) required dialysis. Patients were categorized based on urinary NGAL concentration within five days of hospitalization - <200 ng/ml and ≥200 ng/ml. Twenty patients (58%) had increased urinary NGAL excretion. The severity of D+HUS at enrollment was similar in the two groups. However, children with increased urinary NGAL levels had higher peak BUN and creatinine concentrations (P<0.01) and required dialysis more often, 9/20 versus 1/14 (P=0.024) compared to children with normal excretion. Conclusion: The majority of patients with D+HUS have renal tubular epithelial injury, as evidenced by elevated urinary NGAL excretion. Urinary NGAL levels below 200 ng/ml within five days of hospitalization may be an adjunctive marker that defines less severe renal involvement.
Similar content being viewed by others
References
Trachtman H, Christen C (1999) Hemolytic uremic syndrome: current understanding of the pathogenesis and therapeutic trials and interventions. Curr Opin Pediatr 11:162–168
Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073–1086
Kaplan BA, Meyers KE, Schulman S (1998) The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 9:1126–1133
Andreoli SP, Trachtman H, Acheson DWK, Siegler RL, Obrig TG (2002) Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol 17:293–298
Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DWK, Weiss R, Kaskel FJ, Spitzer A, Hirschman GH (2003) Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: A randomized clinical trial. JAMA 290:1337–1344
Siegler RL (1994) Spectrum of extra-renal involvement in postdiarrheal hemolytic–uremic syndrome. J Pediatr 125:511–518
Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and meta-regression. JAMA 290:1360–1370
Ray PE, Liu XH (2001) Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 16:823–839
Kiyokawa N, Taguchi T, Mori T, Uchida H, Sato N, Takeda T, Fujimoto J (1998) Induction of apoptosis in normal renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J Infect Dis 178:178–184
Hughes AK, Stricklett PK, Kohan DE (1998) Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int 54:426–437
Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035–1050
Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalcin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534–2543
Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J, Devarajan P (2004) Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalcin. J Am Soc Nephrol 15:3073–3082
Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D’Agati V, Devarajan P, Barasch J (2005) Endocytic delivery of lipocalcin–siderophore–iron complex rescues the kidney ischemia–reperfusion injury. J Clin Invest 115:610–621
Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalcin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238
Te Loo DM, Monnens LA, van den Heuvel LP, Gubler MC, Kockx MM (2001) Detection of apoptosis in kidney biopsies of patients with D+ hemolytic uremic syndrome. Pediatr Res 49:413–416
Nestoridi E, Kushak RI, Duguerre D, Grabowski EF, Ingelfinger JR (2005) Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int 67:2254–2266
Schulman SL, Kaplan BS (1996) Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria. Pediatr Nephrol 10:671–674
Lameire N, Van Biesen W, Vanholder R (2005) Acute renal failure. Lancet 365:417–430
Ohlsson S, Wieslander J, Segelmark M (2003) Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin Exp Immunol 131:528–535
Acknowledgements
This work was presented at the Annual Meeting of the American Society of Nephrology, Philadelphia, PA, November 2005. It was supported, in part, by grant DK52147 (HT). PD is supported by grants from the NIH-NIDDK (RO1-DK53289, P50-DK52612, R21-DK070163), a Grant-in-Aid from the American Heart Association Ohio Valley Affiliate, and a Translational Research Initiative Grant from Cincinnati Children’s Hospital Medical Center.
Author information
Authors and Affiliations
Consortia
Corresponding author
Appendix
Appendix
List of participating centers
Administrative center: Howard Trachtman MD, Principal Investigator; Erica Christen RN, Project Coordinator, Schneider Children’s Hospital, New Hyde Park, NY; Data Coordinating Center: Avital Cnaan PhD (Director), Kathleen Gibbs, MSIS, Children’ Hospital of Philadelphia, Philadelphia, PA; Microbiology Core Laboratory: David Acheson MD (Director), Ramona Chitrakar, Thao Ngo, Fred Smith, Michelle Nieves, Sam Caraballo, Tufts-New England Medical Center, Boston, MA; Jilma Patrick, University of Maryland, Baltimore, MD; Data Safety Monitoring Board: Julie Ingelfinger MD (Chairperson), Gladys Hirschman MD, Josephine Briggs MD, John Kusek MD, Daniel Cattran MD, Mitchell B. Cohen MD, Katherine Freeman PhD, Thomas Greene PhD, Solomon Moshe MD; Participating Centers: Howard Trachtman MD, Schneider Children’s Hospital, New Hyde Park, NY; Seth Schulman MD, Children’s Hospital of Philadelphia, Philadelphia, PA; James Springate MD, Children’s Hospital of Buffalo, Buffalo, NY; Frederick Kaskel MD PhD, Montefiore Medical Center, Bronx, NY; Dilys Whyte MD, State University of NY Hospital at Stony Brook, Stony Brook, NY; Robert Weiss MD, New York Medical College/Westchester County Medical Center, Valhalla, NY; Charles McKay MD, duPont Hospital for Children, Wilmington, DE; Lewis Reisman MD, St. Barnabas Hospital for Children, Livingston, NJ; Eduardo Perelstein MD, Cornell University Medical Center, New York, NY; Manju Chandra MD, North Shore University Hospital, Manhasset, NY; Jose Salcedo MD, St. Joseph’s Children’s Hospital, Patterson, NJ; Lynne Weiss MD, Robert Wood Johnson University Hospital, New Brunswick, NJ; William Varade MD, State University of NY Rochester Medical Center, Rochester, NY; Douglas Ford MD, Denver Children’s Hospital, Denver, CO; James Chan MD, Medical College of Virginia, Richmond, VA; Irene Restaino MD, Children’s Hospital of the King’s Daughters, Norfolk, VA; Shashi Nagaraj MD, Wake Forest University/North Carolina Baptist Hospital, Winston-Salem, NC; Victoria Norwood MD, University of Virginia Medical Center, Charlottesville, VA; John Foreman MD, Duke University Medical Center, Durham, NC; Michael Moritz MD, Children’s Hospital of Pittsburgh, Pittsburgh, PA; John Mahan MD, Columbus Children’s Hospital, Columbus, OH; Marva Moxey-Mims MD, Children’s National Medical Center, Washington DC; Barry Warshaw MD, Egleston Children’s Hospital, Atlanta, GA; Verna Yiu MD, University of Alberta Hospital, Edmonton, Alberta, Canada; Andrew Brem MD, Rhode Island Hospital, Providence, RI; Sharon Bartosh MD, University of Wisconsin Hospital, Madison, WI; Sharon Andreoli MD, University of Indiana/Riley Children’s Hospital, Indianapolis, IN; Lawrence Milner MD, Tufts New England Medical Center, Boston, MA; Jens Goebel MD, University of Kentucky Medical Center, Lexington, KY; Dianne Muchant MD, West Virginia University Medical Center, Morgantown, WV; Coral Hanevold MD, Medical College of Georgia, Augusta, GA.
Rights and permissions
About this article
Cite this article
Trachtman, H., Christen, E., Cnaan, A. et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 21, 989–994 (2006). https://doi.org/10.1007/s00467-006-0146-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-006-0146-y